These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 11170947)

  • 1. Randomized, double-blind study in healthy adults to assess the boosting effect of Vaqta or Havrix after a single dose of Havrix.
    Connor BA; Phair J; Sack D; McEniry D; Hornick R; Banerjee D; Jensen E; Kuter B
    Clin Infect Dis; 2001 Feb; 32(3):396-401. PubMed ID: 11170947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and interchangeability of two inactivated hepatitis A vaccines in Chilean children.
    Abarca K; Ibánez I; Perret C; Vial P; Zinsou JA
    Int J Infect Dis; 2008 May; 12(3):270-7. PubMed ID: 17988917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity and safety of an inactivated hepatitis A vaccine in Taiwanese adults and children.
    Lee CY; Huang LM; Lee PI; Chiu HH; Dumas R; Milcamps B; Lin W
    Southeast Asian J Trop Med Public Health; 2000 Mar; 31(1):29-36. PubMed ID: 11023061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults.
    Ashur Y; Adler R; Rowe M; Shouval D
    Vaccine; 1999 May; 17(18):2290-6. PubMed ID: 10403597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, cross-over, controlled comparison of two inactivated hepatitis A vaccines.
    Bryan JP; Henry CH; Hoffman AG; South-Paul JE; Smith JA; Cruess D; Spieker JM; de Medina M
    Vaccine; 2000 Nov; 19(7-8):743-50. PubMed ID: 11115695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised comparison of two inactivated hepatitis A vaccines, Avaxim and Vaqta, given as a booster to subjects primed with Avaxim.
    Clarke P; Kitchin N; Souverbie F
    Vaccine; 2001 Aug; 19(31):4429-33. PubMed ID: 11483268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interchangeability and tolerability of two inactivated hepatitis A vaccines in Chinese children.
    Zhang ZL; Zhu XJ; Wang X; Liang M; Sun J; Liu Y; Gao ZG; Wu JY; Dong XJ; Liu RK; Chen JT; Zhang YQ; Wang W; Zhang LP; Yin W
    Vaccine; 2012 Jun; 30(27):4028-33. PubMed ID: 22537990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Safety and immunogenicity of a new inactivated hepatitis A vaccine].
    Ren A; Ma J; Feng F
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2001 Dec; 15(4):357-9. PubMed ID: 11986726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Field performance of VAQTA (inactivated, purified hepatitis a vaccine) in Chinese children in Jiangsu.
    Wang H; Chen X; Chen Z; Lu W; Poerschke G; Eves K; Gress J; Kuter B
    Southeast Asian J Trop Med Public Health; 2004 Dec; 35(4):949-53. PubMed ID: 15916096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing live attenuated and inactivated hepatitis A vaccines: an immunogenicity study after one single dose.
    Zheng H; Chen Y; Wang F; Gong X; Wu Z; Miao N; Zhang X; Li H; Chen C; Hou X; Cui F; Wang H
    Vaccine; 2011 Nov; 29(48):9098-103. PubMed ID: 21875638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial.
    Dagan R; Amir J; Livni G; Greenberg D; Abu-Abed J; Guy L; Ashkenazi S; Foresner G; Tewald F; Schätzl HM; Hoffmann D; Ibanez R; Herzog C
    Pediatr Infect Dis J; 2007 Sep; 26(9):787-93. PubMed ID: 17721372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatitis A booster vaccine in children after infant immunization.
    Kanra G; Yalcin SS; Kara A; Ozmert E; Yurdakök K
    Pediatr Infect Dis J; 2002 Aug; 21(8):727-30. PubMed ID: 12192159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of three consecutive lots of a new preservative-free inactivated hepatitis A vaccine (Healive): a double-blind, randomized and controlled trial.
    Jiang WP; Chen JT; Wang X; Wang YL; Liu Y; Chen WY; Xu WG; Qiu YZ; Yin WD
    Vaccine; 2008 Apr; 26(18):2297-301. PubMed ID: 18395305
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children.
    Guerra FA; Gress J; Werzberger A; Reisinger K; Walter E; Lakkis H; Grosso AD; Welebob C; Kuter BJ;
    Pediatr Infect Dis J; 2006 Oct; 25(10):912-9. PubMed ID: 17006287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China.
    Li RC; Li Y; Yi N; Huang L; Wan Z; Zhang Y; Rasuli A
    Pediatr Infect Dis J; 2013 Feb; 32(2):e77-81. PubMed ID: 23334341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative immunogenicity and tolerance of Vaqta and Havrix.
    Braconier JH; Wennerholm S; Norrby SR
    Vaccine; 1999 Apr; 17(17):2181-4. PubMed ID: 10367952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interchangeability and tolerability of a virosomal and an aluminum-adsorbed hepatitis A vaccine.
    Bovier PA; Farinelli T; Loutan L
    Vaccine; 2005 Mar; 23(19):2424-9. PubMed ID: 15752828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparable Serologic Responses to 2 Different Combinations of Inactivated Hepatitis A Virus Vaccines in HIV-Positive Patients During an Acute Hepatitis A Outbreak in Taiwan.
    Lin KY; Hsieh SM; Sheng WH; Lo YC; Chuang YC; Cheng A; Pan SC; Chen GJ; Sun HY; Hung CC; Chang SC
    J Infect Dis; 2018 Jul; 218(5):734-738. PubMed ID: 29668951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.